Virpax Pharmaceuticals, Inc., a leader in non-addictive pain management, PTSD, CNS disorders, and antiviral barrier solutions, has unveiled findings from a Dose Range Finding (DRF) study using minipigs for Probudur, a liposomal bupivacaine formulation known for providing both immediate and prolonged analgesia when administered to wound sites.
The DRF study focused on assessing Probudur’s tolerability within an incisional wound healing paradigm in minipigs, where the formulation was directly administered into the tissue near the incision. All participating minipigs showed a positive tolerance to Probudur, with no adverse reactions observed. This ongoing development supports Virpax’s conviction that Probudur is capable of delivering both immediate and enduring pain relief at the site of incisions.
Jatinder Dhaliwal, CEO of Virpax, remarked, “These encouraging results from our pharmacokinetics and safety studies highlight Probudur’s ability to provide quick and lasting relief at the wound site. Completing these studies is a pivotal step towards submitting our Investigational New Drug Application (IND) for Probudur.”
Probudur is being engineered to ensure safe, efficacious pain management throughout the perioperative phase, aiming to significantly diminish or, ideally, eliminate opioid dependence post-surgery for approved uses. By targeting the sodium channel, this local anesthetic hinders pain signals from reaching the brain. Animal models and in vitro studies reveal that Probudur achieves extended pain control, maintaining efficacy for up to 96 hours and relieving pain for up to five days in rat models, with studies indicating gradual bupivacaine release over six days.
Virpax is committed to creating proprietary, non-addictive pain management solutions, leveraging innovative technologies to enhance drug delivery precision and effectiveness.